BMO Capital analyst Etzer Darout initiated coverage of Jasper Therapeutics (JSPR) with an Outperform rating and $63 price target Jasper is a clinical-stage biotechnology company focused on therapeutics targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma with lead asset briquilimab, says the analyst. The firm sees “an opportunity for significant upside,” particularly with its CSU and CIndU programs, given data presented earlier this year, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma
- Jasper Therapeutics Advances in Antibody Therapy Development
- Jasper Therapeutics reports Q3 EPS ($1.24), consensus ($1.07)
- Jasper Therapeutics commences open-label extension study of chronic urticarias
- Jasper Therapeutics management to meet virtually with Jefferies
Questions or Comments about the article? Write to editor@tipranks.com